Frontlight ResearchEarly access
Taking people in United StatesNo phase
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
Key facts
- Who runs it
- Lexeo Therapeutics
- Where
- Ann Arbor, Baltimore, Columbia, Detroit, Redwood City, and Rochester, United StatesSee the 6 sites
- Trial code
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 23 Jan 2024
- Expected to end
- Sept 2027
- Type of study
- Observational
- Record updated
- 16 May 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)
- Documentation of a pathogenic or likely pathogenic truncating variant in PKP2
- Frequent premature ventricular contractions (PVCs)
- Patients must have an ICD placed prior to enrollment
- Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants
Who cannot take part
- A history of prior gene transfer therapy
- A history of other cardiac abnormalities as specified in the protocol
- New York Heart Association symptoms of heart failure of Class IV at the time of consent
- Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Muhammad HussainTaking people
- Johns Hopkins UniversityBaltimore, United StatesContact: Crystal TichnellTaking people
- Northshore University Healthsystem Research InstituteColumbia, United StatesContact: Person*: Lexeo Clinical TrialsTaking people
- Henry Ford HospitalDetroit, United StatesContact: Person*: Lexeo Clinical TrialsTaking people
- Leland Stanford Junior UniversityRedwood City, United StatesContact: Priya NairTaking people
- University of RochesterRochester, United StatesContact: Person*: Lexeo Clinical TrialsTaking people
About the trial
What the trial wants to find out
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)
- Fit questions
- Built from NCT06976606, who can take part
- Record updated
- 16 May 2025